LYPD3, a New Biomarker and Therapeutic Target for Acute Myelogenous Leukemia

Overview of attention for article published in Frontiers in Genetics, March 2022

Altmetric Badge

About this Attention Score

Average Attention Score compared to outputs of the same age
Above-average Attention Score compared to outputs of the same age and source (63rd percentile)

Mentioned by

twitter: 2 X users

Citations

dimensions_citation: 9 Dimensions

Readers on

mendeley: 9 Mendeley

Summary X Dimensions citations

So far, Altmetric has seen 2 X posts from 2 X users, with an upper bound of 6,489 followers.

New article: LYPD3, a New Biomarker and Therapeutic Target for Acute Myelogenous Leukemia https://t.co/zpHtzDHQ2q #AML #leusm #hematology https://t.co/8SqRDBBRHx

01 Apr 2022

Reply Repost Favourite

New Research: LYPD3, a New Biomarker and Therapeutic Target for Acute Myelogenous Leukemia: Background: Acute myelogenous leukemia (AML) is nosocomial with the highest pediatric mortality rates and a relatively poor prognosis. C4.4A(LYPD3) is a… https://t.

11 Mar 2022

Reply Repost Favourite

This page shows the most recent X posts that mention this research output.

Click here to find out how to access more activity.